Evidence map›Paper›PMID 39587463›Full record

ArticleBMC nephrology2024

Nephrology providers' perspective and use of mortality prognostic tools in dialysis patients.

Jennifer Bergeron, Christina Marchese, Colton Jensen, Sean Meagher, Amanda G Kennedy, Bradley Tompkins, Katharine L Cheung

Abstract read
In one paragraph

Article in BMC nephrology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Jennifer BergeronDivision of Nephrology, Department of Medicine, West Virginia University School of Medicine, 1 Medical Center Drive, PO Box 9165, Morgantown, WV, 26506, USA. jennifer.bergeron@hsc.wvu.edu.ORCID 0009-0002-1839-4303
Christina MarcheseDivision of Nephrology, Department of Medicine, The University of Vermont Medical Center, Burlington, VT, USA.
Colton JensenDivision of Nephrology, Department of Medicine, The University of Vermont Medical Center, Burlington, VT, USA.ORCID 0009-0002-9365-8559
Sean MeagherDepartment of Medicine, Beth Israel Deaconess Medical Center, Boston, MA, USA.
Amanda G KennedyDepartment of Medicine Quality Program, The Robert Larner, MD College of Medicine at The University of Vermont, Burlington, VT, USA.ORCID 0000-0002-7540-4961
Bradley TompkinsDepartment of Medicine Quality Program, The Robert Larner, MD College of Medicine at The University of Vermont, Burlington, VT, USA.ORCID 0009-0008-1171-7759
Katharine L CheungDivision of Nephrology, Department of Medicine, The University of Vermont Medical Center, Burlington, VT, USA.ORCID 0000-0002-2282-4778

Funding

NIH National Institutes of Health U54-GM115516
6 · The paper itself

Abstract

backgroundMortality prognostic tools exist to aid in shared decision making with kidney failure patients but are underutilized. This study aimed to elucidate nephrology providers' practice patterns and understand barriers to prognostic tool use.

methodsNephrology providers (8 physicians and 2 nurse practitioners) at an academic medical center underwent semi-structured interviews regarding their experience and perspective on the utility of mortality prognostic tools. Common themes were identified independently by 2 reviewers using grounded theory. Three six-month mortality prognostic tools were applied to the 279 prevalent dialysis patients that the interviewed providers care for. The C statistic was calculated for each tool via logistic regression and subsequent ROC analysis. Nephrology providers reviewed the performance of the prognostication tools in their own patient population. A post interview reassessed perspectives and any change in attitudes regarding the tools.

resultsNephrology providers did not use these mortality prognostic tools in their practice. Key barriers identified were provider concern that the tools were not generalizable to their patients, providers' trust in their own clinical judgement over that of a prognostic tool, time constraints, and lack of knowledge about the data behind these tools. When re-interviewed with the results of the three prognostic tools in their patients, providers thought the tools performed as expected, but still did not intend to use the tools in their practice. They reported that these tools are good for populations, but not individual patients. The providers preferred to use clinical gestalt for prognostication.

conclusionAlthough several well validated prognostic tools are available for predicting mortality, the nephrology providers studied do not use them in routine practice, even after an educational intervention. Other approaches should be explored to help incorporate prognostication in shared-decision-making for patients receiving dialysis.

Indexed as

Attitude of Health PersonnelNephrologyRenal DialysisAgedFemaleHumansKidney Failure, ChronicMaleMiddle AgedNephrologistsNurse PractitionersPractice Patterns, Physicians'PrognosisDialysisKidney failureMortalityPerspectivesPrognosticationQualitativeTools

Identifiers

PMID39587463
PMCPMC11590527

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.